{"name":"Glenmark Specialty S.A.","slug":"glenmark-specialty-s-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"oncology","drugs":[{"name":"GMM-2 NS","genericName":"GMM-2 NS","slug":"gmm-2-ns","indication":"Other","status":"phase_3"},{"name":"GOM-NS","genericName":"GOM-NS","slug":"gom-ns","indication":"Other","status":"phase_3"},{"name":"GSP 301 NS","genericName":"GSP 301 NS","slug":"gsp-301-ns","indication":"Other","status":"phase_3"},{"name":"GSP 301 Placebo NS pH 3.7","genericName":"GSP 301 Placebo NS pH 3.7","slug":"gsp-301-placebo-ns-ph-3-7","indication":"Other","status":"phase_3"},{"name":"GSP 301 Placebo NS pH 7.0","genericName":"GSP 301 Placebo NS pH 7.0","slug":"gsp-301-placebo-ns-ph-7-0","indication":"Other","status":"phase_3"},{"name":"Mometasone furoate NS","genericName":"Mometasone furoate NS","slug":"mometasone-furoate-ns","indication":"Allergic rhinitis","status":"phase_3"},{"name":"Olopatadine HCl NS","genericName":"Olopatadine HCl NS","slug":"olopatadine-hcl-ns","indication":"Allergic rhinitis (nasal spray formulation)","status":"phase_3"}]}],"pipeline":[{"name":"GMM-2 NS","genericName":"GMM-2 NS","slug":"gmm-2-ns","phase":"phase_3","mechanism":"GMM-2 NS is a novel formulation designed to modulate immune or inflammatory pathways, though its exact mechanism requires further clinical characterization.","indications":[],"catalyst":""},{"name":"GOM-NS","genericName":"GOM-NS","slug":"gom-ns","phase":"phase_3","mechanism":"GOM-NS is an investigational drug in phase 3 development by Glenmark Specialty S.A., but its specific mechanism of action is not publicly disclosed.","indications":[],"catalyst":""},{"name":"GSP 301 NS","genericName":"GSP 301 NS","slug":"gsp-301-ns","phase":"phase_3","mechanism":"GSP 301 NS is a nasal spray formulation designed to deliver its active pharmaceutical ingredient through the nasal mucosa for systemic or local therapeutic effect.","indications":[],"catalyst":""},{"name":"GSP 301 Placebo NS pH 3.7","genericName":"GSP 301 Placebo NS pH 3.7","slug":"gsp-301-placebo-ns-ph-3-7","phase":"phase_3","mechanism":"This is a placebo formulation with no active pharmaceutical ingredient.","indications":[],"catalyst":""},{"name":"GSP 301 Placebo NS pH 7.0","genericName":"GSP 301 Placebo NS pH 7.0","slug":"gsp-301-placebo-ns-ph-7-0","phase":"phase_3","mechanism":"This is a placebo formulation with no active pharmaceutical ingredient.","indications":[],"catalyst":""},{"name":"Mometasone furoate NS","genericName":"Mometasone furoate NS","slug":"mometasone-furoate-ns","phase":"phase_3","mechanism":"Mometasone furoate is a corticosteroid that reduces inflammation in the nasal passages by suppressing immune responses and decreasing inflammatory mediator release.","indications":["Allergic rhinitis","Nasal polyps","Chronic rhinosinusitis"],"catalyst":""},{"name":"Olopatadine HCl NS","genericName":"Olopatadine HCl NS","slug":"olopatadine-hcl-ns","phase":"phase_3","mechanism":"Olopatadine HCl is a selective H1-receptor antagonist and mast cell stabilizer that reduces allergic inflammation in the nasal cavity.","indications":["Allergic rhinitis (nasal spray formulation)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-05","type":"regulatory","source":"Express Pharma","summary":"Glenmark Specialty SA receives USFDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation - Express Pharma","headline":"Glenmark Specialty SA receives USFDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiygJBVV95cUxNYUNBdS1EOWI4WTBQM0J3bGN0cFFINkxZN19Ya3M1SEV1allSbmhOdXF0TjhMQWdKUTVxWXhXQlIyMDBlNmFrV3NQSmpObW9pSU9VRnpnNm1najhEUjl0Yl9iZnZ0Zi1PTnJYMmdWZFJDSTBfelZrVmdQSnc2Y2MyNjlRRWoxb2JKMlB4VE9nQkdoeHhGa3BHaFFZRHNMVGlIb0hzdlI0V3UwVUtsUWpGdkRPUngxclp1T1U1UVhFeXk1VjRUUk5UU0ZvbEVjV0xPQ1p3cFZfb3BBTkNGNThYWVJjOFNtZTktUU9kSEcybmp1dUtUN3lvWlNMLWNCM0k5UnNNNU9CYW5tMG5vZWQyVHVUXzVvTkFjdF9CSkhQYndVSncwNHZQclRhSllnUEJoZWM5SmREdjBZZ1BubzdEOUlGNUZiUWJGeGc?oc=5","date":"2026-03-04","type":"regulatory","source":"PR Newswire","summary":"Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, with 180-Day Competitive Generic Therapy Exclusivity - PR Newswire","headline":"Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-03-04","type":"regulatory","source":"The Economic Times","summary":"Glenmark Pharmaceuticals wins USFDA nod for fluticasone inhaler - The Economic Times","headline":"Glenmark Pharmaceuticals wins USFDA nod for fluticasone inhaler","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-04","type":"regulatory","source":"Moneycontrol.com","summary":"Glenmark gets USFDA nod for generic Flovent with 180‑day CGT exclusivity - Moneycontrol.com","headline":"Glenmark gets USFDA nod for generic Flovent with 180‑day CGT exclusivity","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-04","type":"regulatory","source":"Business Standard","summary":"Glenmark Pharma secures USFDA nod for Fluticasone Propionate Inhalation Aerosol - Business Standard","headline":"Glenmark Pharma secures USFDA nod for Fluticasone Propionate Inhalation Aerosol","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPeEExaE9zalBOWnhFRlZkRGU5dlVzYlFXcE4tLUcxX2s0LWN2am9uemg5azRRMVBEb1k3Y09Qcnp6NGxTa0RBV3B5S1Y3MDB5RlN2WW9KQXlUTmloSExiU2JNX3F2eFdCYUNiNzFvS0hEZjN6RGdZRlJMQXR2NjE0bV9ZN2hsVkNNaUs1Mll0VnBYVThiQUp1ekhUMU5MelZnOHFv?oc=5","date":"2026-03-04","type":"regulatory","source":"Trade Brains","summary":"Glenmark Pharma Targets $520 Million U.S. Respiratory Market After FDA Approval - Trade Brains","headline":"Glenmark Pharma Targets $520 Million U.S. Respiratory Market After FDA Approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxNZzdpTFpPWUJXa3Zud0tOSkNZc2ZCbDFxZ0tpMzZhdllBWDdjdGlHOTZlQTJuWUpSMUNwMThSUFpNQWNUR0lBckpjS2ZlUFlCZ2ZwTjhWRVJLSHpIWWJSWV9MOERva2xwOEk4TVFxSnNBV0NwT2R6NzF1NmtCekNiSFBtODAtN0VFRnd3NUtncjZxT0g3V1NoSDdVcUxZbWFvNGJjbVZCZUFKWGoxT0F0UjF5d2dFcnlscVU1LU1SWXF4YmtBelpKUXAzNWRIcGF0NjBMMUV4STlTRjNreEF4NmZBN0lXWk9T?oc=5","date":"2026-03-03","type":"regulatory","source":"scanx.trade","summary":"Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate with 180-Day Exclusivity - scanx.trade","headline":"Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate with 180-Day Exclusivity","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPcFNYa2ozZlRGT196S2g2dW1ZbG51czcwenpMYjRzUE1rSjVZd1hjQmtpOFFHSUw0V1RWLTA1ZVNCVnF3VlFYUnpGLTgzLVpscmlUMTUwQnE2RkF5WHBjOEVmOXphUWFwX0RZZlZoYW4zYU84bVg0cVF6dTFaeVprMzhkaGpfOHZRSm10dHp5TmFoRkZ3Zlg3VHJ5U1F2U2RCUUdSSHRNRVNoODdFdzBXWnJxTTBjUlY1X0FubG1CV1BlZGot?oc=5","date":"2025-12-18","type":"pipeline","source":"BioSpectrum Asia","summary":"Glenmark bags multi-regional rights to Hansoh Pharma's oncology drug for $1 B - BioSpectrum Asia","headline":"Glenmark bags multi-regional rights to Hansoh Pharma's oncology drug for $1 B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxNT2ZGR29sRGdlWTRsYmg2dGtVV2Z2RUxBSUdTbS01Y19fdVRZVldJYzU4UXVMcnlGdlkyUEZLZnNQZEptVWRhXzNVbVNKaGVOM3pUVlZOTzdOcjlaSUdKdFhCLUVJOHhmZ3U4OEx0YldaLW1OeG1iTkd1ajRKcm1BNGRBQnpIWmdsaXAxSi05N1hzZHA0SGtOSHRkSExnQ1k3elNFbTM2cVduVFhJSFpZblozMkx1NzgwYm40ZmEwSklZZFpNQWY5eHVlb0k4TnZsZmI2eVFCNmE1Q0tSWXBNUmhVeFRwMEg5U2Jn0gHwAUFVX3lxTE45Wm1BZUxxd2JZV1pYUVBlZ3BtZHZVblhNMnFQWEVIWHVWeDh5Vy1HWjFncFR4dl9TTk9IWUY0QmQ5cGlmeEdTalh1M2FGMEFnRHN2VWJ2eGlSRDA2dHE4VlVWNzdMejY1RHZ5NHpwcjlrVkItcEw3WEpaQzhIenBDVGZENUtsRHNqeHFZS25kelN3OHVndm1PNEFqNWJobDVoMnJCU3ZQMFhCak9sc1l4VnZDeFlWRU95WXVBSDhOTW5rcHFLRzVnQU0wY3prQjh4ZUJSUFFCcTM0WExGOUY0bUdMUV9ZY0ZWRUJQVGx4bQ?oc=5","date":"2025-12-17","type":"pipeline","source":"ET Pharma","summary":"Glenmark secures multi-regional rights for Hansoh’s lung cancer drug Aumolertinib - ET Pharma","headline":"Glenmark secures multi-regional rights for Hansoh’s lung cancer drug Aumolertinib","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOOXRzZ1prUXFUUnNacm1nUEg4eFBwcUlHU0k3NXRkQm1lZG9vY1U1LXdBVzhWelp3YWZpcTYzYXMwcURlS21BWElxRjEzTEFUWGRmcU9BUTlBOFA0dGUyXzVHbEg3UTV5djQ3bFJkUjdtUlFBNTRYS25uQW1ralk4cQ?oc=5","date":"2025-11-12","type":"regulatory","source":"Healthcare Radius","summary":"China approves Glenmark Pharma’s Ryaltris nasal spray for allergic rhinitis - Healthcare Radius","headline":"China approves Glenmark Pharma’s Ryaltris nasal spray for allergic rhinitis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxNb1gyTk9kRkNtRHJWTjVDTFFBNE5weG5WdElRVWxidk53VjFwQTFzRnJlME1IQlZxYkpSSFVqMlE3NG4yaEJ4MVpOY1lwNHRrUlpMRFRkX20wMEhSbll2VDRfcmo1eFgybVdEOFpfN09BOHZMRlBBOE9rdGNKZ0hsWFhha0ppNGNWczlkZHRjaElFc05yazF4MzlTV2NHbDRZbW5uUS1sUkZfZDFLOHVnZ1g0ZElILXV4NHNxSE9kdE9nRnJVQmlQVXNUMXV0b1FydHpFYmJJRTNsSUlhLVEwM3J1azBfRlRMZHJGMFk2OE0yTFRhZHlpck9tMUdVRW5udk9xUkdvbFp0SFFK?oc=5","date":"2025-11-10","type":"pipeline","source":"Whalesbook","summary":"Glenmark Pharma Scores Big! China Gives Green Light for Allergy Spray RYALTRIS - Stocks Ready to Fly? - Whalesbook","headline":"Glenmark Pharma Scores Big! China Gives Green Light for Allergy Spray RYALTRIS - Stocks Ready to Fly?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxOMC1qczd2RGFTX0FmYS0tYTJoRzN5eFlXODVtNzhMLVBIUlNBLTRUNk1zY1FaZ1cxSE1oX0hoWlJCeFZmd3Q0VnhsbzFVeVNVSGE4ZlB1OGVJa3huTHVGdUVCUWVNNkU5SG5xTE1qQXVjYk9DR3lTaEp3VzVmSU9nM1FFNVhTeWlEUVdpUHMwcl9Wei1XaGVPZ0JHTTY5dlZIekQ4YmFkVEQ4RGtfb2NMdFo0M092QnItUEdGM09TMElQZUlQQ3RuejBwNno2ZFM5ajdqczMzQUkwRXdX?oc=5","date":"2025-09-24","type":"pipeline","source":"BioSpectrum Asia","summary":"Glenmark strengthens oncology portfolio with Hengrui's HER2 targeting ADC for multiple regions - BioSpectrum Asia","headline":"Glenmark strengthens oncology portfolio with Hengrui's HER2 targeting ADC for multiple regions","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_3":7},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}